Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open Label Study of Siremadlin Monotherapy and in Combination With Donor Lymphocyte Infusion as a Treatment for Patients With Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplantation Who Are in Complete Remission But at High Risk for Relapse

Next Previous
Trial Profile

A Phase Ib/II, Open Label Study of Siremadlin Monotherapy and in Combination With Donor Lymphocyte Infusion as a Treatment for Patients With Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplantation Who Are in Complete Remission But at High Risk for Relapse

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Siremadlin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
  • 05 Feb 2024 Status changed from recruiting to discontinued (Study has been stopped following to strategic decision from the Sponsor. Not based on anysafety findings or safety concerns with siremadlin).
  • 23 Nov 2023 This trial has been completed in Germany, according to European Clinical Trials Database record. (End date: 2023-10-26)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top